Results 131 to 140 of about 1,772,527 (156)
Myelodysplastic syndromes and utilisation of blood products in the era of hypomethylating agents
Myelodysplastic syndromes (MDS) are primary bone marrow disorders with clonal abnormalities in hematopoietic stem cells. It leads to ineffective hematopoiesis causing cytopenias as well as functional abnormalities.
Asma Ashraf (7451837)
core
Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN
Naveen Pemmaraju +9 more
doaj +1 more source
Dysregulation of cellular epigenetic machinery is considered a major pathogenetic determinant in many malignancies, including myelodysplastic syndromes (MDS).
Clara Nervi +2 more
exaly +2 more sources
Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia.
Christian Flotho, Michael Lubbert
exaly +2 more sources
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents [PDF]
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival.
Mrinal M Patnaik +2 more
exaly +2 more sources

